A Novel Approach to Carbon-13 Breath Tests

描述（申请人摘要）：稳定同位素医用诊断呼吸 测试具有非侵入性、高度特异性检测 入侵生物或测量器官功能，通常成本低于 竞争测试然而，拥有较低的成本并不总是足够的。那里 是巨大的财政压力和激励，引入测试， 减少医疗保健支出。反同位素稀释（RID） 以显著降低未来呼吸测试的成本， 增加可能的呼吸测试应用的阵列。 该应用的新奇在于管理低成本的RID概念 示踪剂与未标记的底物探针。未标记底物探针 稀释了预期只有标记的CO2排泄曲线， 示踪剂已经被使用。曲线被修改的程度提供了 深入了解特定酶途径的功能。随着许多 可以使用相同的标记示踪剂进行不同的测试 改变未标记的探针。好处包括做呼吸测试 经济上有吸引力，并扩大了示踪剂的可能应用 试验. 我们的长期目标是利用RID技术开发一系列 胃肠道稳定同位素呼吸试验，临床上有用， 成本

DESCRIPTION (Applicant's abstract): Stable isotope medical diagnostic breath tests enjoy the advantages of being non-invasive, highly specific to detecting an invading organism or measuring organ function, and usually lower cost than competing tests. However, having a lower cost is not always sufficient. There is great financial pressure and incentives to introduce tests that dramatically reduce health care expenditures. Reverse Isotope Dilution (RID) was developed to significantly reduce the cost of future breath tests and in the process increase the array of possible breath test applications. The novelty of this application is the RID concept of administering a low cost tracer with an unlabelled substrate probe. The unlabeled substrate probe dilutes the CO2 excretion curve that would be expected had only the labeled tracer been administered. The degree to which the curve is modified provides insight into the functionality of a specific enzymatic pathway. With RID many different tests can be performed using the same labeled tracer but only changing the unlabeled probe. The benefits include making breath tests economically attractive and expanding the possible applications for tracer tests. Our long-term objective is to use RID technology to develop a family of gastrointestinal stable isotope breath tests that are clinically useful and low cost.